Leadership Team

Cuong Do

President and
Chief Executive Officer
Cuong Do, MBA, is President and CEO of BioVie Inc . Prior to his appointment with BioVie, Mr. Do was President of Samsung Global Strategy Group where he helped to set the strategic direction for Samsung Group’s diverse business portfolio. He was previously the Chief Strategy Officer for Merck, a leading US pharmaceuticals company. Mr. Do is a former senior partner at McKinsey & Company, where he spent 17 years helping to build the healthcare, high tech and corporate finance practices. He holds a BA from Dartmouth College, and an MBA from the Tuck School of Business at Dartmouth.

Joseph M. Palumbo

Chief Medical Officer
Joseph M Palumbo, MD, LFAPA, MACPsych, is Chief Medical Officer of BioVie Inc. Prior to his appointment at BioVie, Dr. Palumbo was Chief Medical Officer at Zynerba. He previously held senior worldwide governance roles at Mitsubishi Tanabe Pharma in both the United States and Japan, with earlier leadership experiences in European and American pharma. Dr. Palumbo holds a BA from the University of Pennsylvania and a Doctor of Medicine from the George Washington University School of Medicine. He was a Biological Sciences Training Program Fellow of the National Institutes of Health and Chief Resident for the Abraham Ribicoff Clinical Neuroscience Research Unit at Yale University.

Jonathan Adams

Executive Vice President,
Liver Disease Program
Jonathan Adams, MBA, founded the predecessor company to BioVie in 2007 and has over 30 years of biopharmaceutical industry experience. This includes finance, acquisitions and licensing, technology commercialization, global product launches, marketing and sales force management. At Searle Pharmaceuticals he was a member of the global launch team for Celebrex and performed key roles in product branding, market research, medical education, and other areas. Subsequently, he worked in technology commercialization for next-generation COX-2 inhibitors. After Searle, Mr. Adams worked in account management for healthcare advertising agencies and developed expertise in a wide range of therapeutic areas while helping his clients to launch dozens of new drugs and devices. He served as a marketing leader for Mission Pharmacal’s urology division before dedicating full-time attention to BioVie beginning in 2018. Mr. Adams earned a BS at Cornell University and an MBA at the Tuck School at Dartmouth.

Chris Reading, PhD

Executive Vice President, Neuroscience Research and Development
Chris Reading received his Ph.D. in Biochemistry from UC Berkeley, performed post-doctoral studies in cancer biology at UC Irvine, and joined MD Anderson Cancer Center and the University of Texas, Graduate School of Biomedical Sciences in Houston for 13 years, where he became Associate Professor of Medicine in the Department of Developmental Therapeutics with a joint appointment in the Department of Tumor Biology. He then accepted a position at Systemix / Novartis in Palo Alto, where he became Vice President of Product and Process Development. From there, he moved to San Diego where he has spent over 15 years on the NE3107 platform development at Harbor Therapeutics. He has over 35 years of research and drug development experience, and over 130 peer-reviewed scientific publication, and has authored numerous patents in the areas of monoclonal antibodies, cell separation technologies, stem cell transplantation, and sterol drug development.

Clarence Ahlem

Executive Vice President, Neuroscience Product Development
Clarence Ahlem has more than 30 years of pharmaceutical development experience. His scientific breadth includes synthetic bifunctional antibodies, hematopoietic stem cell purification, and pharmacological characterization of the dehydroepiandrosterone metabolome and associated pharmaceutical science. Clarence worked for four years at UCSD prior to joining the Therapeutics Division at Hybritech in San Diego, CA, where he worked for six years developing synthetic bifunctional antibodies and their applications to cancer therapy. Mr. Ahlem left Hybritech to initiate product development at Systemix, Inc. in Palo Alto, CA, where he was manager of bio-organic chemistry for 4 years. He left Systemix to join Prolinx Biochemistry in Bothell, WA, and moved to San Diego in 1997 to join Hollis-Eden Pharmaceuticals (subsequently Harbor BioSciences and Harbor Therapeutics), where he was Vice President of Product Development until 2014.

Penelope Markham, PhD

Executive Vice President, Liver Disease Research and Development
Penelope Markham, PhD, led the development of modified terlipressin compounds for LAT Pharma LLC, the predecessor company to BioVie, for 7 years prior to its acquisition by BioVie. Previously, she spent 15 years in immunology, infectious disease, bacteriology and drug discovery research. Dr. Markham was a co-founder and Research Director for Influx, Inc. engaged in antibiotic drug discovery. She has been a member of NIH grant review panels and consulted for several pharmaceutical companies in a variety of therapeutic areas including Orphan drug development. Dr. Markham has more than 20 publications in peer-reviewed journals and three patents. She holds a BS in Biochemistry from the University College Cork, Ireland, an MS from Strathclyde University, Scotland, and a PhD from Rush University, Chicago.

Wendy Kim, CPA

Chief Financial Officer
Wendy Kim, CPA, has over 25 years’ experience in accounting and finance. As a CFO prior to BioVie, she oversaw corporate finance and operational groups, closed 8 M&A transactions, secured bank financings, developed and implemented new business strategies, managed risk, and implemented new financial policies and procedures. As a public accountant with BDO USA LLP, she served for 8 years in the firm’s SEC Department and provided accounting, SEC filing reviews and other business consultative services to companies and engagement teams. Her areas of expertise include: Strategic and Financial Planning, Banking Relations and Fund Raising, Risk Management, Investor Relations, SEC Reporting/External Reporting Systems, Merger & Acquisitions, and Financial modeling/Forecasting. Ms. Kim earned her BBA in accounting & finance at California State University.
Forward Looking Statements
This website contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties, and assumptions that could cause BioVie’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements.
Sign-up to follow our progress
* indicates required
9120 Double Diamond Parkway
Suite 1400
Reno, NV 89521
(775) 888-3162

Email: info@biovieinc.com
Web: www.bioviepharma.com
© Copyright 2012 - 2021 | BioVie Inc. | ALL RIGHTS RESERVED |